Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Enrico Pelz"'
Autor:
Matthias Christgen, Leonie Donata Kandt, Wiebke Antonopoulos, Stephan Bartels, Mieke R VanBockstal, Martin Bredt, Maria Jose Brito, Henriette Christgen, Cecile Colpaert, Bálint Cserni, Gábor Cserni, Maximilian E Daemmrich, Raihanatou Danebrock, Franceska Dedeurwaerdere, Carolien HM vanDeurzen, Ramona Erber, Christine Fathke, Henning Feist, Maryse Fiche, Claudia Aura Gonzalez, Natalie D terHoeve, Loes Kooreman, Till Krech, Glen Kristiansen, Janina Kulka, Florian Laenger, Marcel Lafos, Ulrich Lehmann, Maria Dolores Martin‐Martinez, Sophie Mueller, Enrico Pelz, Mieke Raap, Alberto Ravarino, Tanja Reineke‐Plaass, Nora Schaumann, Anne‐Marie Schelfhout, Maxim DeSchepper, Jerome Schlue, Koen Van de Vijver, Wim Waelput, Axel Wellmann, Monika Graeser, Oleg Gluz, Sherko Kuemmel, Ulrike Nitz, Nadia Harbeck, Christine Desmedt, Giuseppe Floris, Patrick WB Derksen, Paul J vanDiest, Anne Vincent‐Salomon, Hans Kreipe
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 8, Iss 2, Pp 191-205 (2022)
Abstract Invasive lobular breast carcinoma (ILC) is the second most common breast carcinoma (BC) subtype and is mainly driven by loss of E‐cadherin expression. Correct classification of BC as ILC is important for patient treatment. This study asses
Externí odkaz:
https://doaj.org/article/315199064a574f7f8e979a65ce71d4f6
Autor:
Sherko Kuemmel, Oleg Gluz, Mattea Reinisch, Athina Kostara, Iris Scheffen, Monika Graeser, Kerstin Luedtke-Heckenkamp, Andreas Hartkopf, Felix Hilpert, Angela Kentsch, Carsten Ziske, Reinhard Depenbusch, Michael Braun, Jens Blohmer, Christine zu Eulenburg, Matthias Christgen, Stephan Bartels, Hans Kreipe, Enrico Pelz, Peter Schmid, Nadia Harbeck
Publikováno v:
Cancer Research. 82:P2-13
Background: De-escalating strategies seem promising inHER2-positive early breast cancer (EBC) and chemo-free regimens are thus of keyinterest. Recent data have underlined the role of tumor immunogenicity inresponse to de-escalated neoadjuvant anti-HE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9c55b0b73a0dc08cdb1deaa3ffae875
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-03
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-03
Autor:
Nadia Harbeck, Ulrike Nitz, Hans Heinrich Kreipe, Friedrich Feuerhake, Cornelia Kolberg-Liedtke, Hua Ni, Ronald Kates, Christine zu Eulenburg, Enrico Pelz, Hans Holger Fischer, Andrea Stefek, Toralf Reimer, Helmut Forstbauer, Claudia Schumacher, Katja Krauss, Rachel Wuerstlein, Jochem Potenberg, Michael Braun, Doris Augustin, Eva-Maria Grischke, Sherko Kuemmel, Jenci Palatty, Matthias Christgen, Daniel Ulbrich-Gebauer, Claudia Biehl, Oleg Gluz, Monika Graeser
Supplementary Table 1 lists genes comprising the RNA expression signatures measured with the BC360 panel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e60314eda6d7136a291f05f0aa7b39c
https://doi.org/10.1158/1078-0432.22490620.v1
https://doi.org/10.1158/1078-0432.22490620.v1
Autor:
Nadia Harbeck, Ulrike Nitz, Hans Heinrich Kreipe, Friedrich Feuerhake, Cornelia Kolberg-Liedtke, Hua Ni, Ronald Kates, Christine zu Eulenburg, Enrico Pelz, Hans Holger Fischer, Andrea Stefek, Toralf Reimer, Helmut Forstbauer, Claudia Schumacher, Katja Krauss, Rachel Wuerstlein, Jochem Potenberg, Michael Braun, Doris Augustin, Eva-Maria Grischke, Sherko Kuemmel, Jenci Palatty, Matthias Christgen, Daniel Ulbrich-Gebauer, Claudia Biehl, Oleg Gluz, Monika Graeser
Supplementary Figure 3 shows association between RNA signatures and overall survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb83951221fbad8da3405291383ceb0
https://doi.org/10.1158/1078-0432.22490623
https://doi.org/10.1158/1078-0432.22490623
Autor:
Nadia Harbeck, Hans Heinrich Kreipe, Christine zu Eulenburg, Katarzyna Jóźwiak, Enrico Pelz, Monika Graeser, Rachel Wuerstlein, Claudia Schumacher, Bahriye Aktas, Christoph Uleer, John Hackmann, Mathias Warm, Michael Braun, Helmut Forstbauer, Eva-Maria Grischke, Laia Paré, Ronald Kates, Daniel Gebauer, Mohammad Parsa Mohammadian, Sherko Kuemmel, Matthias Christgen, Aleix Prat, Cornelia Kolberg-Liedtke, Ulrike Nitz, Oleg Gluz
Purpose:Although optimal treatment in early triple-negative breast cancer (TNBC) remains unclear, de-escalated chemotherapy appears to be an option in selected patients within this aggressive subtype. Previous studies have identified several pro-immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7beb568b022ee30ffa8db4063d737ea4
https://doi.org/10.1158/1078-0432.c.6532775
https://doi.org/10.1158/1078-0432.c.6532775
Autor:
Nadia Harbeck, Hans Heinrich Kreipe, Christine zu Eulenburg, Katarzyna Jóźwiak, Enrico Pelz, Monika Graeser, Rachel Wuerstlein, Claudia Schumacher, Bahriye Aktas, Christoph Uleer, John Hackmann, Mathias Warm, Michael Braun, Helmut Forstbauer, Eva-Maria Grischke, Laia Paré, Ronald Kates, Daniel Gebauer, Mohammad Parsa Mohammadian, Sherko Kuemmel, Matthias Christgen, Aleix Prat, Cornelia Kolberg-Liedtke, Ulrike Nitz, Oleg Gluz
Supplementary Data from De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f676ae1086b15da98952f8ec352432d
https://doi.org/10.1158/1078-0432.22488641.v1
https://doi.org/10.1158/1078-0432.22488641.v1
Autor:
Nadia Harbeck, Hans Heinrich Kreipe, Christine zu Eulenburg, Katarzyna Jóźwiak, Enrico Pelz, Monika Graeser, Rachel Wuerstlein, Claudia Schumacher, Bahriye Aktas, Christoph Uleer, John Hackmann, Mathias Warm, Michael Braun, Helmut Forstbauer, Eva-Maria Grischke, Laia Paré, Ronald Kates, Daniel Gebauer, Mohammad Parsa Mohammadian, Sherko Kuemmel, Matthias Christgen, Aleix Prat, Cornelia Kolberg-Liedtke, Ulrike Nitz, Oleg Gluz
Supplementary Figure from De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36e431586ea0bfa0351596de28e9b491
https://doi.org/10.1158/1078-0432.22488632
https://doi.org/10.1158/1078-0432.22488632
Autor:
Nadia Harbeck, Ulrike Nitz, Hans Heinrich Kreipe, Friedrich Feuerhake, Cornelia Kolberg-Liedtke, Hua Ni, Ronald Kates, Christine zu Eulenburg, Enrico Pelz, Hans Holger Fischer, Andrea Stefek, Toralf Reimer, Helmut Forstbauer, Claudia Schumacher, Katja Krauss, Rachel Wuerstlein, Jochem Potenberg, Michael Braun, Doris Augustin, Eva-Maria Grischke, Sherko Kuemmel, Jenci Palatty, Matthias Christgen, Daniel Ulbrich-Gebauer, Claudia Biehl, Oleg Gluz, Monika Graeser
Purpose:To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) and survival in the Phase II WSG-ADAPT HER2+/HR− trial (NCT01817452).Experimental Desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ac3e075fb428952cc341942b7e5308
https://doi.org/10.1158/1078-0432.c.6533188
https://doi.org/10.1158/1078-0432.c.6533188
Autor:
Nadia Harbeck, Hans Heinrich Kreipe, Christine zu Eulenburg, Katarzyna Jóźwiak, Enrico Pelz, Monika Graeser, Rachel Wuerstlein, Claudia Schumacher, Bahriye Aktas, Christoph Uleer, John Hackmann, Mathias Warm, Michael Braun, Helmut Forstbauer, Eva-Maria Grischke, Laia Paré, Ronald Kates, Daniel Gebauer, Mohammad Parsa Mohammadian, Sherko Kuemmel, Matthias Christgen, Aleix Prat, Cornelia Kolberg-Liedtke, Ulrike Nitz, Oleg Gluz
Supplementary Table from De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01f94f242c0ea20f310c82d51f61e1c1
https://doi.org/10.1158/1078-0432.22488626.v1
https://doi.org/10.1158/1078-0432.22488626.v1
Autor:
Monika Graeser, Sherko Kuemmel, Oleg Gluz, Friedrich Feuerhake, Valery Volk, Daniel Ulbrich-Gebauer, Claudia Biehl, Mattea Reinisch, Athina Kostara9, Iris Scheffen, Kerstin Luedtke-Heckenkamp, Andreas Hartkopf, Felix Hilpert, Angela Kentsch, Carsten Ziske, Reinhard Depenbusch, Michael Braun, Jens-Uwe Blohmer, Christine zu Eulenburg, Matthias Christgen, Ronald Kates, Stephan Bartels, Hans-Heinrich Kreipe, Enrico Pelz, Peter Schmid, Nadia Harbeck
Publikováno v:
Cancer Research. 83:P5-02
Background In unselected HER2+ early breast cancer (EBC), de-escalated chemotherapy-free neoadjuvant therapy (NAT) with dual HER2-blockade induces pCR rates of only 20%-40%. In order to achieve pCR rates by de-escalated therapy comparable to those ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::642ffe7703d53c70f7429d547298171f
https://doi.org/10.1158/1538-7445.sabcs22-p5-02-03
https://doi.org/10.1158/1538-7445.sabcs22-p5-02-03